I propose to take Questions Nos. 1100 to 1102, inclusive, 1157 and 1158 together.
The immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). The NIAC is a committee of the Royal College of Physicians of Ireland comprising of experts in a number of specialties including infectious diseases, paediatrics and public health. A Health Technology Assessment which includes a cost benefit analysis is carried out prior to any new vaccine being considered. This has a vital role in ensuring that care technologies, including vaccines, are used in a manner appropriate to their ability to maximise health gain and achieve value for money. The NIAC has not made any recommendation in relation to the use of Bexsero in the primary childhood immunisation programme in Ireland. However NIAC has issued guidance in relation to the use of Bexsero in the control of clusters or outbreaks of Meningococcal B disease. I have sought a report from the HSE concerning the recent cases in Cavan and Westmeath.